Brief: AcelRx Pharmaceuticals Receives Notice From Nasdaq On Its Bid Price Deficiency
15/06/2023 21:17
June 15 (Reuters) - AcelRx Pharmaceuticals Inc ACRX.O :
* ACELRX PHARMACEUTICALS INC- RECEIVED NOTICE FROM NASDAQ
CONFIRMING THAT THE COMPANY HAS CURED ITS BID PRICE DEFICIENCY
* ACELRX PHARMACEUTICALS INC- REGAINED COMPLIANCE WITH
MINIMUM BID
PRICE RULE
Further company coverage: ACRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Talphera
See all newsTalphera Inc reports results for the quarter ended June 30 - Earnings Summary
Talphera Inc expected to post a loss of 7 cents a share - Earnings Preview
Talphera Q1 net loss narrows as costs rise on higher development spending
Talphera Q4 net loss widens as operating expenses rise
Brief: Talphera Announces 50% Enrollment Milestone In Ongoing Nephro-Crrt Registrational Trial